Showing results (431-440 of 567) with videos related to
Sort By:
Pageof 57
Journal of the American Academy of Dermatology|December 17, 2022
Monkeypox outbreak, vaccination, and treatment implications for the dermatologic patient: Review and interim guidance from the Medical Dermatology SocietyAnusha M Kumar, Steven T Chen, Joseph F Merola, et al.Dermatology and Therapy|November 22, 2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled TrialsJoseph F Merola, Alice B Gottlieb, Andreas Pinter, et al.Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.The Journal of Rheumatology|April 16, 2022
2021 GRAPPA Meet the Experts Session: A Summary of PresentationsApril W Armstrong, Rasika M Reddy, Oliver FitzGerald, et al.Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.Pageof 57